A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment
Public ClinicalTrials.gov record NCT04908189. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the safety and efficacy of deucravacitinib versus placebo for the treatment of participants with active PsA who are naïve to biologic disease modifying antirheumatic drugs or had previously received TNFα inhibitor treatment.The long term extension period will provide additional long-term safety and efficacy information.
Study identification
- NCT ID
- NCT04908189
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 729 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 15, 2021 (Actual)
- Primary completion
- Nov 7, 2024 (Actual)
- Completion
- Nov 12, 2026 (Estimated)
- Last update posted
- Sep 11, 2026
2021 – 2026
United States locations
- U.S. sites
- 24
- U.S. states
- 19
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 0149 | Mountain Brook | Alabama | 35223 | — |
| Local Institution - 0212 | Sacramento | California | 95815 | — |
| Local Institution - 0188 | Whittier | California | 90602 | — |
| Local Institution - 0192 | Skokie | Illinois | 60076 | — |
| Local Institution - 0203 | Hopkinsville | Kentucky | 42240 | — |
| Local Institution - 0195 | Baton Rouge | Louisiana | 70836 | — |
| Local Institution - 0169 | Cumberland | Maryland | 21502 | — |
| Local Institution - 0034 | Okemos | Michigan | 48864 | — |
| Local Institution - 0133 | Eagan | Minnesota | 55121 | — |
| Local Institution - 0109 | Hattiesburg | Mississippi | 39402 | — |
| Local Institution - 0108 | New York | New York | 10003 | — |
| Local Institution - 0186 | Rochester | New York | 14642 | — |
| Local Institution - 0196 | Charlotte | North Carolina | 28277 | — |
| Local Institution - 0180 | Cleveland | Ohio | 44106 | — |
| Local Institution - 0189 | Oklahoma City | Oklahoma | 73116 | — |
| Local Institution - 0147 | Portland | Oregon | 97239 | — |
| Local Institution - 0016 | Duncansville | Pennsylvania | 16635 | — |
| Local Institution - 0182 | Summerville | South Carolina | 29486 | — |
| Local Institution - 0167 | Lubbock | Texas | 79424 | — |
| Local Institution - 0070 | Mesquite | Texas | 75150 | — |
| Local Institution - 0184 | Plano | Texas | 75024 | — |
| Local Institution - 0187 | Seattle | Washington | 98122 | — |
| Local Institution - 0190 | Franklin | Wisconsin | 53132 | — |
| Local Institution - 0175 | Milwaukee | Wisconsin | 53217 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 114 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04908189, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 11, 2026 · Synced Oct 31, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04908189 live on ClinicalTrials.gov.